Clinical trial Recruiting at 1 site Observational Ages 18 and up

Communication support for ventilated intensive care patients

Official title: Communication Enhancement Among Ventilated Patients in Intensive Care : Feasibility of Implementing "JIB-TourS cARe" High Technology Device With Eye Tracker

Run by University Hospital, Tours · NCT07251530 · Data updated 2026-11-12

This project will try an eye-tracking tablet (JIB-Tours care) to help conscious, ventilated adults in ICU who cannot speak communicate with caregivers and family.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment60 (estimated)
SponsorUniversity Hospital, Tours
Academic / other
Locations3 sites (Le Mans and 2 other locations)
StatusRecruiting
StartedMarch 19, 2026
Main results expectedJune 1, 2027
Study endsJune 1, 2027
Registry record updatedMay 4, 2026
Trial IDNCT07251530 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Conscious adult ICU patients who are intubated or have an inflated-cuff tracheostomy, can open and close their eyes on command, and speak French.

Probably not a fit

Patients with uncorrected visual or hearing impairments, reduced consciousness, non-French speakers, or those under legal guardianship are unlikely to benefit from this system.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

JIB-Tours care is a tablet-based communication system controlled by eye-tracking that first runs a brief test to determine a patient’s comprehension level and then automatically selects one of three tailored communication interfaces. The device is intended for conscious, intubated or tracheostomized adult ICU patients who can open and close their eyes on command. The observational program will implement the system at participating ICUs and record whether the comprehension test can be completed, the interface switches correctly, and patients can deliver intended messages. The system was co-designed with ICU clinicians, former patients, and relatives to match real-world needs.

Why it matters

Potential benefit: If successful, it could allow non-speaking ventilated patients to express needs and feelings more reliably, lowering anxiety and improving care decisions.

How similar studies have gone: Previous small pilots of eye-tracking and augmentative communication in critical care have shown feasibility and improved patient communication, but larger controlled evidence remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Intubated ventilated ICU patient
* Hospitalized patient with an inflated cuff tracheostomy
* conscious patient, able to open and close eyes on demand
* of-age patient
* French speaking

Exclusion Criteria:

* Patient with uncorrected visual impairment or hearing deficiency
* Known guardianship or trusteeship at the time of inclusion
* Known pregnant women at the time of inclusion and lactating patients
* opposed to the processing of personal data

Where it's running

  • Intensive care, University Hospital
    Tours, France
    Recruiting
  • Intensive care, Hospital, Le MANS
    Le Mans, France
    Not yet recruiting
  • Intensive care, University Hospital, Orléans
    Orléans, France
    Not yet recruiting

Study contacts

  • Principal investigator: Laetitia BODET-CONTENTIN, MD PhD — Intensive care, University Hospital, Tours
  • Study coordinator: Laetitia BODET-CONTENTIN, Doctor
  • Email: laetitia.bodet@chu-tours.fr
  • Phone: 0247479861

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.